Thoracic complications associated with targeted cancer therapies [19]
| Adverse event |
Class of Agent |
| Pneumonitis |
PD-1/PD-L1 inhibitor (Nivolumab,
Pembrolizumab, Atezolizumab) mTOR inhibitor (Everolimus, Temsirolimus) EGFR inhibitor (Erlotinib, Gefitinib, Afatinib, Osimertinib) ALK inhibitor (Crizotinib, Alectinib, Ceritinib) HER2 inhibitor (Trastuzumab) CD20 antibody (Rituximab) |
| Sarcoid-like rxn |
CTLA-4 inhibitor (Ipilimumab) PD-1/PD-L1 inhibitor (Novolumab, Pembrolizumab, Atezolizumab) |
| Pulmonary hemorrhage |
VEGF inhibitor (Bevacizumab, Sorafenib,
Sunitinib) |
| Pulmonary embolism |
VEGF inhibitor (Bevacizumab, Sorafenib, Sunitinib) |
| Pleural effusion |
BCR-ABL kinase inhibitor (Dasatinib,
Imatinib, Nilotinib) |
| Pneumothorax |
Tyrosine kinase inhibitor (Pazopanib) VEGF inhibitor (Bevacizumab, Sorafenib, Sunitinib) |
